Association of PTEN polymorphisms with susceptibility to hepatocellular carcinoma in a Han Chinese population

DNA and Cell Biology

Volumn 30, Issue 4, 2011, Pages 229-234

  Ding, Jun ^a   Gao, Yuzhen ^a   Liu, Rengyu ^b   Xu, Fei ^a   Liu, Haiyan ^a  

^a SOOCHOW UNIVERSITY   (China)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADULT; AGED; ALLELE; ARTICLE; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; INDEL MUTATION; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALCOHOL DRINKING; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, HEPATOCELLULAR; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; INDEL MUTATION; LINKAGE DISEQUILIBRIUM; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PTEN PHOSPHOHYDROLASE; RISK; SMOKING;

EID: 79953250579     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2010.1126     Document Type: Article

References (42)

1. Agrawal, S., Pilarski, R., and Eng, C. (2005). Different splicing defects lead to differential effects downstream of the lipid and protein phosphatase activities of PTEN. Hum Mol Genet 14, 2459-2468. (Pubitemid 41418007)
2. Akey, J., Jin, L., and Xiong, M. (2001). Haplotypes vs single marker linkage disequilibrium tests: what do we gain? Eur J Hum Genet 9, 291-300. (Pubitemid 32366698)
3. Bae, J.J., Rho, J.W., Lee, T.J., Yun, S.S., Kim, H.J., Choi, J.H., Jeong, D., Jang, B.C., and Lee, T.Y. (2007). Loss of heterozygosity on chromosome 10q23 and mutation of the phosphatase and tensin homolog deleted from chromosome 10 tumor suppressor gene in Korean hepatocellular carcinoma patients. Oncol Rep 18, 1007-1013.
4. Brendle, A., Lei, H., Brandt, A., Johansson, R., Enquist, K., Henriksson, R., Hemminki, K., Lenner, P., and Försti, A. (2008). Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker. Carcinogenesis 29, 1394-1399.
5. Caldwell, S., and Park, S.H. (2009). The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol 44, 96-101.
6. Chin, L.J., Ratner, E., Leng, S., Zhai, R., Nallur, S., Babar, I., Muller, R.U., Straka, E., Su, L., Burki, E.A., Crowell, R.E., Patel, R., Kulkarni, T., Homer, R., Zelterman, D., Kidd, K.K., Zhu, Y., Christiani, D.C., Belinsky, S.A., Slack, F.J., and Weidhaas, J.B. (2008). A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases nonsmall cell lung cancer risk. Cancer Res 68, 8535-8540.
7. El-Serag, H.B., and Rudolph, K.L. (2007). Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132, 2557-2576. (Pubitemid 46890874)
8. Faul, F., Erdfelder, E., Lang, A.G., and Buchner, A. (2007). G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39, 175-191.
9. Gao, Y., He, Y., Ding, J., Wu, K., Hu, B., Liu, Y., Wu, Y., Guo, B., Shen, Y., Landi, D., Landi, S., Zhou, Y., and Liu, H. (2009). An insertion/deletion polymorphism at miRNA-122-binding site in the interleukin-1 alpha 3′ untranslated region confers risk for hepatocellular carcinoma. Carcinogenesis 30, 2064-2069.
10. Ge, H., Cao, Y.Y., Chen, L.Q., Wang, Y.M., Chen, Z.F., Wen, D.G., Zhang, X.F., Guo, W., Wang, N., Li, Y., and Zhang, J.H. (2008). PTEN polymorphisms and the risk of esophageal carcinoma and gastric cardiac carcinoma in a high incidence region of China. Dis Esophagus 21, 409-415.
11. Gershwin, M.E., and Mackay, I.R. (2008). The causes of primary biliary cirrhosis: convenient and inconvenient truths. Hepatology 47, 737-745. (Pubitemid 351280742)
12. Gershwin, M.E., Selmi, C., Worman, H.J., Gold, E.B., Watnik, M., Utts, J., Lindor, K.D., Kaplan, M.M., and Vierling, J.M. (2005). Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 42, 1194-1202. (Pubitemid 43112687)
13. Guldberg, P., thor Straten, P., Birck, A., Ahrenkiel, V., Kirkin, A.F., and Zeuthen, J. (1997). Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 57, 3660-3663.
14. Hennessy, B.T., Smith, D.L., Ram, P.T., Lu, Y., and Mills, G.B. (2005). Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4, 988-1004.
15. Hu, T.H., Huang, C.C., Lin, P.R., Chang, H.W., Ger, L.P., Lin, Y.W., Changchien, C.S., Lee, C.M., and Tai, M.H. (2003). Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer 97, 1929-1940.
16. Jiang, Z., Pore, N., Cerniglia, G.J., Mick, R., Georgescu, M.M., Bernhard, E.J., Hahn, S.M., Gupta, A.K., and Maity, A. (2007). Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. Cancer Res 67, 4467-4473. (Pubitemid 46815097)
17. Jones, D.E. (2003). Pathogenesis of primary biliary cirrhosis. J Hepatol 39, 639-648.
18. Jou, Y.S., Lee, C.S., Chang, Y.H., Hsiao, C.F., Chen, C.F., Chao, C.C., Wu, L.S., Yeh, S.H., Chen, D.S., and Chen, P.J. (2004).Clustering of minimal deleted regions reveals distinct genetic pathways of human hepatocellular carcinoma. Cancer Res 64, 3030-3036. (Pubitemid 38581401)
19. Kaplan, M.M., and Gershwin, M.E. (2005). Primary biliary cirrhosis. N Engl J Med 353, 1261-1273. (Pubitemid 41345948)
20. Kong, D., Suzuk, A., Zou, T.T., Sakurada, A., Kemp, L.W., Wakatsuki, S., Yokoyama, T., Yamakawa, H., Furukawa, T., Sato, M., Ohuchi, N., Sato, S., Yin, J., Wang, S., Abraham, J.M., Souza, R.F., Smolinski, K.N., Meltzer, S.J., and Horii, A. (1997). PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet 17, 143-144.
21. Landi, D., Gemignani, F., Naccarati, A., Pardini, B., Vodicka, P., Vodickova, L., Novotny, J., Försti, A., Hemminki, K., Canzian, F., and Landi, S. (2008). Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. Carcinogenesis 29, 579-584. (Pubitemid 351404875)
22. Ma, D.Z., Xu, Z., Liang, Y.L., Su, J.M., Li, Z.X., Zhang, W., Wang, L.Y., and Zha, X.L. (2005). Down-regulation of PTEN expression due to loss of promoter activity in human hepatocellular carcinoma cell lines. World J Gastroenterol 11, 4472-4477. (Pubitemid 41150385)
23. Maehama, T., and Dixon, J.E. (1998). The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273, 13375-13378. (Pubitemid 28268370)
24. Morris, R.W., and Kaplan, N.L. (2002). On the advantage of haplotype analysis in the presence of multiple disease susceptibility alleles. Genet Epidemiol 23, 221-233.
25. Oda, K., Okada, J., Timmerman, L., Rodriguez-Viciana, P., Stokoe, D., Shoji, K., Taketani, Y., Kuramoto, H., Knight, Z.A., Shokat, K.M., and McCormick, F. (2008). PIK3CA cooperates with other phosphatidylinositol 3′-kinase pathway mutations to effect oncogenic transformation. Cancer Res 68, 8127-8136.
26. Pezzolesi, M.G., Li, Y., Zhou, X.P., Pilarski, R., Shen, L., and Eng, C. (2006). Mutation-positive and mutation-negative patients with Cowden and Bannayan-Riley-Ruvalcaba syndromes associated with distinct 10q haplotypes. Am J Hum Genet 79, 923-934.
27. Phillips, L.S., Thompson, C.L., Merkulova, A., Plummer, S.J., Tucker, T.C., Casey, G., and Li, L. (2009). No association between phosphatase and tensin homolog genetic polymorphisms and colon cancer. World J Gastroenterol 15, 3771-3775.
28. Rasheed, B.K., Stenzel, T.T., McLendon, R.E., Parsons, R., Friedman, A.H., Friedman, H.S., Bigner, D.D., and Bigner, S.H. (1997). PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res 57, 4187-4190. (Pubitemid 27413420)
29. Rhei, E., Kang, L., Bogomolniy, F., Federici, M.G., Borgen, P.I., and Boyd, J. (1997). Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res 57, 3657-3659. (Pubitemid 27381202)
30. Shi, Y.Y., and He, L. (2005). SHEsis: a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 15, 97-98. (Pubitemid 41653949)
31. Shin, H.D., Park, B.L., Kim, L.H., Jung, J.H., Kim, J.Y., Yoon, J.H., Kim, Y.J., and Lee, H.S. (2003). Interleukin-10 haplotype associated with increased risk of hepatocellular carcinoma. Hum Mol Genet 12, 901-906. (Pubitemid 36504032)
32. Sun, Y., St. Clair, D.K., Fang, F., Warren, G.W., Rangnekar, V.M., Crooks, P.A., and St. Clair, W.H. (2007). The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-kB inhibition and enhanced by the presence of PTEN. Mol Cancer Ther 6, 2477-2486.
33. Suzuki, H., Freije, D., Nusskern, D.R., Okami, K., Cairns, P., Sidransky, D., Isaacs, W.B., and Bova, G.S. (1998). Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 58, 204-209. (Pubitemid 28047054)
34. Tang, Z.Y. (2000). Hepatocellular carcinoma. J Gastroenterol Hepatol 15, G1-G7.
35. Walsh, P.S., Metzger, D.A., and Higuchi, R. (1991). Chelex 100 as a medium for simple extraction of DNA for PCR-based typing from forensic material. Biotechniques 10, 506-513.
36. Wan, X.W., Jiang, M., Cao, H.F., He, Y.Q., Liu, S.Q., Qiu, X.H., Wu, M.C., and Wang, H.Y. (2003). The alteration of PTEN tumor suppressor expression and its association with the histopathological features of human primary hepatocellular carcinoma. J Cancer Res Clin Oncol 129, 100-106. (Pubitemid 36470091)
37. Wang, Z.X., Wang, H.Y., and Wu, M.C. (2001). Identification and characterization of a novel human hepatocellular carcinoma-associated gene. Br J Cancer 85, 1162-1167.
38. Wu, X., Senechal, K., Neshat, M.S., Whang, Y.E., and Sawyers, C.L. (1998). The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 95, 15587-15591. (Pubitemid 29018743)
39. Yin, Y., and Shen, W.H. (2008). PTEN: a new guardian of the genome. Oncogene 27, 5443-5453.
40. Yuan, T.L., and Cantley, L.C. (2008). PI3K pathway alterations in cancer: variations on a theme. Oncogene 27, 5497-5510.
41. Zhang, C.Z., Han, L., Zhang, A.L., Fu, Y.C., Yue, X., Wang, G.X., Jia, Z.F., Pu, P.Y., Zhang, Q.Y., and Kang, C.S. (2010). Micro-RNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer 10, 367.
42. Zhang, L., Liu, T., Liu, H., Gao, J., and Gu, C. (2000). Loss and inactivation of PTEN/MMAC1/TEP1 gene in lung cancer. Zhonghua Bing Li Xue Za Zhi 29, 85-88.